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Abstract Peri-procedural bleeding complications are
feared adverse events in patients undergoing transcatheter
aortic valve implantation (TAVI). Little is known about the
implications of peri-procedural bleeding on clinical out-
come. In a prospective single-center registry of consecutive
patients undergoing TAVI, we investigated incidence,
predictors and clinical consequences of life-threatening and
major bleeding as defined by the Valve Academic Research
Consortium. Among 389 consecutive patients undergoing
TAVI by a transfemoral (79.2 %), transapical (19.6 %) or
trans-subclavian (1.3 %) approach between July 2007 and
October 2011, life-threatening or major peri-procedural
bleeding events occurred in 64 (16.4 %) and 125 patients
(32.1 %), respectively. Patients with peri-procedural
bleeding events had a higher logistic EuroSCORE, more
advanced renal disease, and were more symptomatic as
assessed by New York Heart Association functional class
at baseline as compared to patients with no bleeding. Life-
threatening bleeding was associated with a higher all-cause
(17.2 vs 5.6 vs 3.0 %, p \ 0.001) and cardiovascular
mortality (10.9 vs 5.6 vs 2.5 %, p = 0.02) at 30 days
compared to patients with major bleeding or no bleeding.
Multivariate analysis identified transapical access (OR 2.6,
95 % CI 1.4–4.8; p = 0.002), glomerular filtration rate
\30 ml/min (OR 2.3, 95 % CI 1.1–4.7, p = 0.031), and
diabetes (OR 1.8, 95 % CI 1.001–3.2, p = 0.049) as
independent predictors of life-threatening, peri-procedural
bleeding. Life-threatening bleeding complications in
patients undergoing TAVI are associated with increased
mortality. Renal impairment, diabetes, and transapical
approach were identified as independent risk factors for
life-threatening bleeding events.
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Introduction
Transcatheter aortic valve Implantation improves survival
in inoperable patients with severe aortic stenosis [1] and is
a treatment alternative to surgical aortic valve replacement
in patients at high peri-procedural risk [2].
Bleeding complications have been associated with
adverse clinical outcome in patients undergoing percuta-
neous coronary interventions for treatment of coronary
artery disease, and are related to access site [3], vascular
access sheath diameter, as well as antiplatelet and anti-
thrombotic regimen [4, 5]. TAVI is performed with the use
of large vascular access sheaths in case of a transfemoral
approach (16–20 French), and requires surgical access in
case of transapical and transsublcavian interventions,
which increase the risk of bleeding complications. Life-
threatening peri-procedural bleeding as assessed by the
Valve Academic Research Consortium (VARC) criteria
was observed in up to every fourth patient in recent
observational TAVI studies [6–10]. Moreover, bleeding
complications were associated with an increased risk of
death in the PARTNER A trial comparing TAVI with
surgical aortic valve replacement among patients at
increased risk (HR 2.11, 95 % CI 1.41–3,17, p \ 0.001)
[2].
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The objective of the present study was to investigate the
incidence, predictors and implications of peri-procedural
bleeding in a prospective single-center TAVI registry.
Methods
Patient population
Patients with severe symptomatic aortic stenosis at
increased risk for surgical aortic valve replacement were
consecutively included in a prospective single-center reg-
istry initiated in August 2007. Eligibility for TAVI was
discussed in the Heart Team consisting of interventional
cardiologists and cardiac surgeons. For an approximate
estimate of the surgical risk the logistic EuroScore and the
STS score were applied. Patients with valve-in-valve
implantation for degenerated aortic bioprostheses were
excluded from this analysis. Standard evaluation for eli-
gibility to undergo TAVI included right and left heart
catheterization, CT angiography of the aortic root and the
peripheral vessels as well as transthoracic and trans-
esophageal echocardiography. Treatment allocation was
determined in an interdisciplinary Heart Team discussion
and the selection of access site and device were based on
anatomical characteristics including peripheral vascular
diameter, vascular tortuosity, annular and vessel calcifica-
tion, and annulus dimension. The registry was approved by
the local ethics committee and all subjects gave written,
informed consent.
Procedures
TAVI was performed by transfemoral, transapical or trans-
subclavian access using the Medtronic CoreValve or the
Edwards Sapien Valve as described previously [7].
Transfemoral TAVI was performed in the majority of
patients under local anesthesia and conscious sedation.
Peri-procedural treatment consisted of unfractionated hep-
arin (70–100 U/kg), aspirin 100 mg qd and clopidogrel
(300 mg loading one day prior to the procedure followed
by 75 mg qd for 3–6 months) plus three doses of a pro-
phylactic antibiotic treatment.
Data collection
Standardized follow-up was performed by clinical visits or
telephone interviews at 1 month, 1 year, and yearly
thereafter. Clinical adverse events were evaluated by
review of medical records and discharge letters collected
from treating hospitals, primary care physicians, and car-
diologists. All potential adverse events were adjudicated by
a clinical event committee of interventional cardiologists
and cardiac surgeons.
Definitions
Clinical endpoints were defined according to the criteria
proposed by the Valve Academic Research Consortium
(VARC) [11]. Cardiovascular death was defined as any
death due to a proximate cardiac cause or death of
unknown cause, as well as all procedure-related deaths and
death caused by non-coronary vascular conditions such as
cerebrovascular disease, pulmonary embolism, or other
vascular disease. Peri-procedural myocardial infarction
was determined by new ischemic symptoms or signs in the
presence of elevated cardiac biomarkers (two or more post-
procedure samples that were [6–8 h apart with a 20 %
increase in the second sample and a peak value exceeding
10x the 99th percentile upper reference limit (URL), or a
peak value exceeding 59 the 99th percentile URL with
new pathological Q waves in at least two contiguous leads)
within 72 h after the index procedure. Major stroke was
considered in case of a rapid onset of focal or global
neurological deficit of C24 h duration requiring therapeutic
intervention, or documentation of a new intracranial defect
using MRI or CT-scan. Life-threatening or disabling
bleeding included [1] bleeding into a critical area or organ
such as the pericardial space, or [2] bleeding causing
hypovolemic shock or requiring vasopressors or surgery, or
[3] bleeding with an overt source of bleeding with a
decrease in haemoglobin C5 g/dl or packed red blood cells
(PRBC) transfusion C4 units. Major bleeding included
overt bleeding associated with a decrease in haemoglobin
level C3.0 g/dl. Access site complications were classified
as major in case of access-related vascular injuries leading
to either death, need for blood transfusions (C4 units),
percutaneous or surgical intervention, or irreversible end-
organ damage. Minor vascular complications encompassed
failure of percutaneous access site closure resulting in
interventional or surgical correction. The modified RIFLE
classification (risk, injury, failure, low output, end-stage
kidney disease) was used for the definition of kidney injury
and was based upon changes in serum creatinine within
72 h after the procedure. Stage 1 was determined as an
increase of serum creatinine to 150–200 % (or an increase
of C26.4 lmol/l), stage 2 was defined as an increase of
baseline creatinine to 200–300 %, and stage 3 was diag-
nosed in case of an increase in creatinine of C300 % with
an acute increase of at least 44 lmol/l. Anemia at baseline
was defined according to the definition provided by the
World Health Organization (WHO) as a haemoglobin
concentration of less than 120 g/l in female patients and
\130 g/l in male patients.
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Statistical analysis
Statistical analyses were performed using SPSS Statistics
Version 17.0. Continuous variables are presented as
mean ± standard deviation (SD) and were compared by
means of a ANOVA test. Categorical data are expressed
as frequency (percentages), and were compared using the
Chi-square and Fishers exact tests as appropriate. Survival
was estimated using the Kaplan–Meier method. A p value
\0.05 was considered statistically significant. A multi-
variate analysis was performed using the following
parameters: age, gender, body mass index, diabetes,
peripheral vascular disease, renal impairment (glomerular
filtration rate \30 ml/min), and type of access.
Results
Between August 2007 an October 2011, 389 consecutive
patients underwent TAVI for severe symptomatic valvular
aortic stenosis by transfemoral (79.2 %), transapical
(19.5 %) or trans-subclavian (1.3 %) access. Bleeding
complications were the most common peri-procedural
adverse events and occurred in 48.6 % of all patients. Life-
threatening bleeding events were encountered in 64
patients (16.4 %) and were related to vascular access site
complications in 31.3 % of cases. Major bleeding events
were observed in 125 patients (32.1 %) and were associ-
ated with access site complications in 20.0 % of cases.
Baseline characteristics of patients with and without
bleeding complications are summarized in Tables 1 and 2.
Patients with peri-procedural bleeding had a higher logistic
EuroSCORE, more advanced renal disease, and were more
symptomatic as assessed by New York Heart Association
functional class. There was no significant difference with
regard to concomitant revascularization procedures
(Table 3). Patients with life-threatening bleeding more
commonly belonged to the group undergoing TAVI by
transapical access (35.9 %) compared to patients with
major bleeding (20.8 %) or no bleeding (13.5 %)
(p = 0.006). Patients suffering from peri-interventional
life-threatening bleeding had a significantly higher all-
cause (17.2 vs 3.0, p \ 0.001) and cardiovascular mortality
(10.9 vs 2.5 %, p = 0.01), as well as a trend towards a
higher rate of myocardial infarction (3.2 vs 0 %,
p = 0.057) at 30 days compared to patients with no
bleeding. Conversely, patients with major bleeding com-
pared to those without bleeding showed no differences in
terms of all-cause death (5.6 vs 3.0 %, p = 0.258), car-
diovascular death (5.6 vs 2.5 %, p = 0.225), or myocardial
infarction (Table 4). In line with an increased peri-proce-
dural risk, patients with life-threatening bleeding had
impaired long-term survival during a follow-up period up
to three years, which was mainly determined by early
events (Fig. 1). In addition, post-interventional renal
impairment was more frequently encountered among
patients with life-threatening bleeding compared to patients
with major or no bleeding (Table 4).
Predictors of life-threatening bleeding were evaluated in
a multivariable analysis. Transapical access (OR 2.6, 95 %
CI 1.4–4.8; p = 0.002), renal impairment (glomerular
filtration rate \30 ml/min; OR 2.3, 95 % CI 1.1–4.7;
p = 0.031), and diabetes (OR 1.8, 95 % CI 1.001–3.2;
p = 0.049) were identified as independent predictors of
life-threatening peri-procedural bleeding.
Discussion
The salient findings of the present study can be summa-
rized as follows: (1) life-threatening peri-procedural
bleeding events were observed in 16 % of patients and
were related to access site complications in one out of three
patients. (2) Peri-interventional life-threatening bleeding
was associated with an increased risk of mortality at
30 days. (3) Distinct risk factors which increase the risk of
a life-threatening bleeding event include renal impairment,
diabetes, and a transapical access route.
Our analysis is in line with the findings of previous
studies reporting a high rate of major or life-threatening
bleeding complications among patients undergoing TAVI.
The incidence of peri-procedural bleeding events according
to the VARC criteria was comparable to previous studies
reporting rates of life-threatening bleeding between 5 and
26 % and of major bleeding between 2 and 38 % [6, 8–10].
The wide range in bleeding complications across various
studies may be related at least in part to small sample size
and the lack of independent event adjudication. Of note, the
rigorous VARC criteria classify the transfusion of two or
more PRBC as major bleeding, which explains to a large
extent the high rate of bleeding events found in the present
cohort. Especially among patients with anemia at baseline,
a strategy to transfuse PRBC prior or only after TAVI will
substantially impact on the rate of major bleeding adverse
events. Of note, more than 50 % of the overall population
had a anemia at baseline and were not prophylactically
transfused pre-procedurally.
This explains in part the fact that bleeding events were
driven by vascular access site complications in 31 % of the
patients with life-threatening bleeding, and in 20 % of the
patients with major bleeding events only. Our data do not
demonstrate an impact of major bleeding events on clinical
outcome with respect to mortality although the number of
included patients is too small to conclusively address this
issue. Conversely, a life-threatening bleeding complication
substantially increased the risk of short-term mortality and
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therefore requires careful attention. A meticulous screening
for the evaluation of the optimal access site is of paramount
importance. For instance, in a transfemoral case with
heavily calcified arteries, a surgical cut-down may be
considered instead of a pure percutaneous approach. To
facilitate closure of the access site a technique of
provisional balloon occlusion of the iliofemoral axis might
reduce the risk of access site bleeding substantially [12].
Similar to our own experience, an analysis focusing on
bleeding complications in the PARTNER A trial revealed a
twofold increased risk of death for patients with bleeding
events [2]. Several reasons may account for the adverse
Table 1 Baseline clinical characteristics
Overall
N = 389
No bleeding
N = 200
Major bleeding
N = 125
Life-threat. bleeding
N = 64
p Value
Age (years, mean ± SD) 82.5 ± 5.8 82.0 ± 6.1 83.4 ± 5.1 82.3 ± 6.0 0.105
Females (n/%) 224/57.6 115/57.5 69/55.2 40/62.5 0.630
BMI (kg/m2, mean ± SD) 26.2 ± 5.1 26.7 ± 5.2 25.6 ± 4.9 25.8 ± 4.8 0.112
Cardiac risk factors
Hypertension (n/%) 303/77.9 155/77.5 99/79.2 49/76.6 0.901
Current smoker (n/%) 48/12.4 22/11.1 20/16.0 6/9.4 0.306
Diabetes mellitus (n/%) 105/27.0 51/25.5 30/24.0 24/37.5 0.112
Positive family history (n/%) 73/18.8 45/22.6 18/14.4 10/15.6 0.142
Glomerular filtration rate 52.7 ± 21.8 56.2 ± 23.8 48.7 ± 17.9 43.3 ± 19.1 \0.001
Anemiaa 229/58.9 124/62.0 65/52.0 40/62.5 0.166
Hemoglobin (g/l, mean ± SD) 121 ± 16 121 ± 15 122 ± 16 119 ± 17 0.581
Hematocrit (% ± SD) 36 ± 5 36 ± 4 36 ± 5 36 ± 5 0.645
Thrombocytes before intervention (9109/l, mean ± SD) 220 ± 78 219 ± 87 219 ± 64 225 ± 76 0.866
International normalized ratio (INR)b 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.2 1.3 ± 0.3 0.875
Past medical history
Prior MI (n/%) 61/15.7 28/14.0 23/18.4 10/15.6 0.569
Prior PCI (n/%) 94/24.2 44/22.0 35/28.0 15/23.4 0.465
CABG (n/%) 72/18.5 35/17.5 26/20.8 11/17.2 0.725
Previous stroke (n/%) 30/7.7 17/8.5 10/8.0 3/4.7 0.603
PVD (n/%) 87/22.4 40/20.0 34/27.2 13/20.3 0.289
COPD (n/%) 72/18.7 42/21.0 21/17.2 9/14.3 0.432
Symptoms
NYHA functional class (mean ± SD) 2.7 ± 0.9 2.7 ± 0.7 2.6 ± 0.8 2.9 ± 0.7 0.045
Angina (n/%) 123/31.6 65/32.5 40/32.0 18/28.1 0.802
Syncope (n/%) 47/12.1 26/13.1 11/8.8 10/15.6 0.333
Cardiac rhythm
Atrial fibrillation 103/27.0 17/26.6 30/24.0 56/29.2 0.597
Prior pacemaker (n/%) 39/10.1 19/9.5 13/10.5 7/10.9 0.928
Risk assessment
Log. EuroSCORE (%, mean ± SD) 24.3 ± 14.2 23.1 ± 14.4 24.1 ± 13.2 28.3 ± 15.0 0.041
STS score (%, mean ± SD) 6.8 ± 5.3 6.3 ± 5.2 7.3 ± 5.4 7.4 ± 5.0 0.155
Medical treatment
Acetylsalicylic acid (n/%) 237/61.7 121/61.1 76/61.3 40/64.5 0.884
Clopidogrel (n/%) 69/18.0 33/16.7 28/22.6 8/12.9 0.213
Oral anticoagulation (n/%) 106/27.5 54/27.3 32/25.8 20/31.7 0.686
MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, PVD peripheral vascular disease, NYHA
New York Heart Association (mean ± standard deviation), EuroSCORE European System for Cardiac Operative Risk Evaluation, STS society of
thoracic surgeons
a According to the WHO definition (120 mg/l for women and \130 mg/l for men)
b Among patients under oral anticoagulation only
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outcome of these patients: first, life-threatening bleeding
might induce prolonged ischemia and hypotension result-
ing in end organ damage. Second, bleeding due to severe
vascular access complications may require bailout inter-
ventions with their associated risks. Third, bleeding per se
is known as surrogate marker for adverse clinical outcome
as evidenced in previous PCI studies [13]. Forth, non-
access related bleeding events such as intracranial, upper
gastrointestinal or retroperitoneal bleeding events may
have deleterious consequences. Fifth, the adverse outcome
Table 2 Baseline characteristics II
Overall
N = 389
No bleeding
N = 200
Major bleeding
N = 125
Life-threat. bleeding
N = 64
p Value
LVEF (%, mean ± SD) 52 ± 15 52 ± 15 52 ± 15 51 ± 14 0.967
Mean gradient (mmHg, mean ± SD) 44 ± 17 44 ± 17 46 ± 16 41 ± 16 0.241
AVA (cm2, mean ± SD) 0.6 ± 0.2 0.6 ± 0.2 0.6 ± 0.2 0.6 ± 0.2 0.239
Coronary artery disease (n/ %) 247/63.5 121/60.5 84/67.2 42/65.6 0.441
PAS pressure (mmHg, mean ± SD) 51 ± 17 50 ± 16 51 ± 18 54 ± 18 0.254
LVEF left ventricular ejection fraction, AVA aortic valve area, PAS pulmonary artery systolic pressure
Table 3 Procedural characteristics
Overall
N = 389
No bleeding
N = 200
Major bleeding
N = 125
Life-threat. bleeding
N = 64
p Value
Revascularization 0.824
Concomitant PCI 63/16.2 29/14.5 11/17.6 12/18.8
Staged PCI 35/9.0 19/9.5 12/9.6 4/6.3
Aortic valve implantation 0.006
Transfemoral MCV (n/ %) 220/56.6 122/61.0 73/58.4 25/39.1
Trans-subclavian MCV (n/ %) 5/1.3 2/1.0 2/1.6 1/1.6
Transfemoral ES (n/ %) 88/22.6 49/24.5 24/19.2 15/23.4
Transapical ES (n/ %) 76/19.5 27/13.5 26/20.8 23/35.9
MCV Medtronic CoreValve bioprosthesis, ES Edwards Sapien bioprosthesis, PCI percutaneous coronary intervention
Table 4 Clinical outcome at 30 days
Overall
N = 389
No bleeding
N = 200
Major bleeding
N = 125
Life-threat. bleeding
N = 64
p Value
All cause mortality (n/ %) 24/6.2 6/3.0 7/5.6 22/17.2 \0.001
Cardiovascular mortality (n/ %) 19/4.9 5/2.5 7/5.6 7/10.9 0.022
Myocardial infarction (n/ %) 2/0.5 0/0 0/0 2/3.2 0.006
Major stroke (n/ %) 14/3.7 7/3.6 6/4.9 1/1.6 0.534
Access-site related complications \0.001
Major (n/ %) 30/7.7 6/3.0 8/6.4 16/25.0
Minor (n/ %) 42/10.8 21/10.5 17/13.6 4/6.3
Valve-related re-interventions 8/2.1 4/2.0 2/1.6 3/3.1 0.781
Number of PRBC (n, mean ± SD) 1.1 ± 2.3 0.1 ± 0.4 0.9 ± 1.0 4.4 ± 4.2 \0.001
Renal failure \0.001
RIFLE stage 1 (n/ %) 44/11.3 15/7.5 15/12.0 14/21.9
RIFLE stage 2 (n/ %) 5/1.3 3/1.5 1/0.8 1/1.6
RIFLE stage 3 (n/ %) 15/3.9 4/2.0 2/1.6 9/14.1
RIFLE risk, injury, failure, loss, end-stage kidney disease, PRBC packed red blood cells
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may be related to the discontinuation of antiplatelet and
antithrombotic treatment. Finally, blood transfusions per se
are known to impact adversely on clinical outcome.
The multivariate analysis identified predictors for
bleeding like renal impairment which has been established
as a risk factor for bleeding also in patients undergoing PCI
which may be related to impaired platelet function [14].
Diabetic patients might be at increased risk of vascular
access site complications due to smaller vessel diameter
and more diffuse vessel disease. The transapical access
which requires a lateral thoracotomy and opening of the
thorax as well as the use of very large introducer sheaths is
accompanied by higher risk of blood loss and transfusion.
Transapical access can be understood as a surrogate for
peripheral vascular disease and may mask the risk of
bleeding associated with peripheral vascular disease in case
of a transfemoral access. Last but not least, clinical expe-
rience demonstrates that the risk of bleeding has been
reduced with the introduction of smaller sheath sizes and
growing experience of the operators.
Rates of life-threatening and major bleeding across groups
according to antithrombotic and antiplatelet regimen (single
antiplatelet therapy only, vitamin K antagonist only, dual
antiplatelet therapy, antiplatelet therapy in combination with
vitamin K antagonist) did not show any significant differ-
ence. This may be attributable to several underlying reasons:
First, numbers of patients in each group and numbers of
events are modest. Second, the individual treatment regimen
was not randomly allocated and is subject to a selection bias.
And finally, the rates of bleeding were not adjusted for other
risk factors for bleeding events.
Conclusion
Anemia at baseline is a common finding in TAVI patients.
Life-threatening bleeding complications but not major
bleeding events according to VARC are associated with
increased mortality. Renal impairment, diabetes, and
transapical approach were identified as independent risk
factors for life-threatening bleeding events.
Disclosures Drs. Windecker and Wenaweser are Proctors for
Medtronic CoreValve and Edwards Lifesciences. Supported by an
unrestricted research grant of Medtronic to the University of Berne.
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